COVID-19 represents a stress test of sorts for our global healthcare system that will hopefully lead to positive changes over the long-term. In the short-term, there are pressing concerns about the feasibility of continuing clinical development in the context of widespread transmission of COVID-19. To remain viable, sponsors will need to consider trial site networks as partners to continue bringing important therapies to patients in need. This can be best achieved through maintaining a thorough site relationship strategy for ongoing programs as part of a more holistic approach to trial design. Read more here.
(Source: Mark Brown; Applied Clinical Trials; 10/20/20)